The latest price target for Galmed Pharmaceuticals (NASDAQ:GLMD) was reported by Maxim Group on July 24, 2023. The analyst firm set a price target for $4.00 expecting GLMD to rise to within 12 months (a possible 45.45% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Galmed Pharmaceuticals (NASDAQ:GLMD) was provided by Maxim Group, and Galmed Pharmaceuticals upgraded their buy rating.

The last upgrade for Galmed Pharmaceuticals Ltd happened on July 24, 2023 when Maxim Group raised their price target to $4. Maxim Group previously had a hold for Galmed Pharmaceuticals Ltd.

The last downgrade for Galmed Pharmaceuticals Ltd happened on August 8, 2022 when Maxim Group changed their price target from N/A to N/A for Galmed Pharmaceuticals Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Galmed Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Galmed Pharmaceuticals was filed on July 24, 2023 so you should expect the next rating to be made available sometime around July 24, 2024.

While ratings are subjective and will change, the latest Galmed Pharmaceuticals (GLMD) rating was a upgraded with a price target of $0.00 to $4.00. The current price Galmed Pharmaceuticals (GLMD) is trading at is $2.75, which is within the analyst’s predicted range.